These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11338069)

  • 1. Ridogrel enemas in distal ulcerative colitis.
    Auwerda JJ; Zijlstra FJ; Tak CJ; van den Ingh HF; Wilson JH; Ouwendijk RJ
    Eur J Gastroenterol Hepatol; 2001 Apr; 13(4):397-400. PubMed ID: 11338069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis.
    Casellas F; Papo M; Guarner F; Antolín M; Segura RM; Armengol JR; Malagelada JR
    Eur J Gastroenterol Hepatol; 1995 Mar; 7(3):221-6. PubMed ID: 7743303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies.
    Tytgat GN; Van Nueten L; Van De Velde I; Joslyn A; Hanauer SB
    Aliment Pharmacol Ther; 2002 Jan; 16(1):87-99. PubMed ID: 11856082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease.
    Carty E; Macey M; McCartney SA; Rampton DS
    Aliment Pharmacol Ther; 2000 Jun; 14(6):807-17. PubMed ID: 10848666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication.
    De Cree J; Geukens H; Gutwirth P; De Clerck F; Vercammen E; Verhaegen H
    Int Angiol; 1993 Mar; 12(1):59-68. PubMed ID: 8376914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease.
    Hoet B; Arnout J; Van Geet C; Deckmyn H; Verhaeghe R; Vermylen J
    Thromb Haemost; 1990 Aug; 64(1):87-90. PubMed ID: 2148849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension.
    Ritter JM; Barrow SE; Doktor HS; Stratton PD; Edwards JS; Henry JA; Gould S
    Hypertension; 1993 Aug; 22(2):197-203. PubMed ID: 8340155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ridogrel. R 68070.
    Drugs R D; 1999 Mar; 1(3):270-2. PubMed ID: 10566044
    [No Abstract]   [Full Text] [Related]  

  • 9. Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease.
    Carty E; Rampton DS; Schneider H; Rutgeerts P; Wright JP
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1323-9. PubMed ID: 11552902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ridogrel in the setting of percutaneous transluminal coronary angioplasty.
    Timmermans C; Vrolix M; Vanhaecke J; Stammen F; Piessens J; Vercammen E; De Geest H
    Am J Cardiol; 1991 Aug; 68(5):463-6. PubMed ID: 1872272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
    Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).
    Circulation; 1994 Feb; 89(2):588-95. PubMed ID: 8313547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
    Vandeplassche G; Hermans C; Somers Y; Van de Werf F; de Clerck F
    J Am Coll Cardiol; 1993 Apr; 21(5):1269-79. PubMed ID: 8459087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study.
    Sandborn WJ; Tremaine WJ; Leighton JA; Lawson GM; Zins BJ; Compton RF; Mays DC; Lipsky JJ; Batts KP; Offord KP; Hurt RD; Green J
    Aliment Pharmacol Ther; 1997 Aug; 11(4):663-71. PubMed ID: 9305473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ridogrel as an adjunct to thrombolysis in acute myocardial infarction.
    van der Wieken LR; Simoons ML; Laarman GJ; Van den Brand M; Nijssen KM; Dellborg M; Hermens W; Vrolik W
    Int J Cardiol; 1995 Nov; 52(2):125-34. PubMed ID: 8749872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial.
    Steinhart AH; Hiruki T; Brzezinski A; Baker JP
    Aliment Pharmacol Ther; 1996 Oct; 10(5):729-36. PubMed ID: 8899080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placental transfer of the thromboxane synthetase inhibitor ridogrel in the late-pregnant ewe.
    Schneider TJ; Struijk PC; Wallenburg HC
    Eur J Obstet Gynecol Reprod Biol; 1999 Sep; 86(1):83-7. PubMed ID: 10471147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ridogrel, a new platelet antiaggregant molecule with a double mechanism of action. A pharmacological and clinical profile].
    Di Perri T; Notari M; Assogna G
    Recenti Prog Med; 1991 Oct; 82(10):533-40. PubMed ID: 1759039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ridogrel improves maternal/fetal homeostasis in an ovine model of pregnancy-induced hypertension.
    Keith JC; Endo Y; Warwick K; Keith KE; Brugh S; Rowles TK
    Prostaglandins; 1994 Mar; 47(3):247-63. PubMed ID: 8016393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.
    Sinha A; Nightingale J; West KP; Berlanga-Acosta J; Playford RJ
    N Engl J Med; 2003 Jul; 349(4):350-7. PubMed ID: 12878742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.